| Species |
Human |
| Protein Construction |
IFN gamma/IFNG (Gln24-Gly161)
Accession # P01579 |
His |
Avi |
| N-term |
|
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized IFN gamma/IFNG, His & Avi, Human at 5μg/ml (100μl/well) on the plate can bind Human IFN gamma R1, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
19.1 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 20-35 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Interferon-gamma (IFN gamma) is a cytokine that plays physiologically important roles in promoting innate and adaptive immune responses. The absence of IFN gamma production or cellular responsiveness in humans and experimental animals significantly predisposes the host to microbial infection, a result that validates the physiologic importance of this cytokine in preventing infectious disease. |
| Synonyms |
Interferon-gamma; Interferon-γ; interferon; gamma; IFG; IFI; IFN gamma; IFNγ; IFN γ |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
